[go: up one dir, main page]

AR066475A1 - Compuestos nitrogenados condensados, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos particularmente, en el tratamiento del dolor y/o la vejiga hiperactiva. - Google Patents

Compuestos nitrogenados condensados, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos particularmente, en el tratamiento del dolor y/o la vejiga hiperactiva.

Info

Publication number
AR066475A1
AR066475A1 ARP080101934A ARP080101934A AR066475A1 AR 066475 A1 AR066475 A1 AR 066475A1 AR P080101934 A ARP080101934 A AR P080101934A AR P080101934 A ARP080101934 A AR P080101934A AR 066475 A1 AR066475 A1 AR 066475A1
Authority
AR
Argentina
Prior art keywords
alkyl
pyrrolo
pyrimidin
dihydro
cycloalkyl
Prior art date
Application number
ARP080101934A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39943763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066475(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR066475A1 publication Critical patent/AR066475A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula 1, una sal farmacéuticamente aceptable del mismo, un diastereomero, un enantiomero, o una mezcla del mismo, donde R1 y R2 son independientemente seleccionados de hidrogeno, alquiI C1-6-C(=O)-, alquil C1-6,alquenil C2-6, cicloalquil C3-7, cicloalquil C3-7-4alquil C1-6, cicloalquil C3-7 fusionado con un fenil, cicloalquil C3-7 fusionado con un fenil y heteroaril C2-6, heterociclil C1-14, heterociclil C1-14-alquiI C1-6, aril C6-10, aril C6-10-alquiI C1-6, o R1 y R2 juntos con el nitrogeno unido a estos forman un heterociclil C2-9; donde dichos alquiI C1-6-C(=O)-, alquil C1-6, alquenil C2-6, cicloalquil C3-7, cicloalquil C3-7-4alquil C1-6, cicloalquil C3-7 fusionado con un fenil, heterociclil C1-14, heterociclil C1-14-alquiI C1-6, aril C6-10, aril C6-10-alquiI C1-6 y heterociclil C2-9 son opcionalmente sustituidos por uno o más grupos seleccionados de, halogeno, ciano, nitro, alcoxi C1-6, haloalcoxi C1-4, alquil C1-6, alquil C1-6halogenado, cicioalquil C3-6, cicloalcoxi C3-6, cicloalquil C3-6-alcoxi C1-4, -(CH2)m-C(=O)NR7R8, -(CH2)m-S(=O)2NR7R8, -(CH2)mNH- C(=O)NR7R8, -(CH2)m-N(R7)C(=O)R8, -(CH2)m-N(R7)C(=O)-OR8, -(CH2)m-C(=O)-OR7, -(CH2)m-C(=O)R7, -(CH2)m-S(=O)2R7, -(CH2)m-S(=O)R7, -(CH2)m-SR7, -(CH2)m-O-C(=O)-R7, -(CH2)m-OR7, -(CH2)m-NR7R8, hidroxi, heterociclil C1-14-alquil C0-4, fenil, bencil, feniletil, donde dichos heterociclil C1-14-alquil C0-4, fenil, bencil o fenetil son opcionalmente sustituido por uno o másgrupos seleccionados de halogeno, ciano, nitro, oxo, alcoxi C1-6, haloalcoxi C1-4, alquil C1-6, alquil C1-6 halogenado, cicloalquil C3-6, cicloalcoxi C3-6, -(CH2)m-C(=O)NR7R8, -C(=O)-(CH2)m-NR7R8, -(CH2)m-S(=O)2NR7R8, -(CH2)mNH-C(=O)NR7R8, -(CH2)m-N(R7)C(=O)R8, -(CH2)m-N(R7)C(=O)-OR8, -(CH2)m-C(=O)-OR7, -(CH2)m-C(=O)R7, -(CH2)m-S(=O)2R7, -(CH2)m-S(=O)R7, -(CH2)m-SR7, -(CH2)m-O-C(=O)-R7, -(CH2)m-OR7, -(CH2)m-NR7R8 e hidroxi; R3 y R4 son independientemente seleccionados de hidrogeno, alquil C1-6, alquenil C2-6, cicloalquil C3-8, cicloalquil C3-8-alquil C1-6, aril C6-10, aril C6-10-alquiI C1-6, heterociclil C3-6 y heterociclil C3-6-alquiI C1-6; o R3 y R4 juntos con el nitrogeno unido a estos forman un heterociclil C2-9; donde dichos alquilC1-6, alquenil C2-6, cicloalquil C3-8, cicloalquil C3-8-alquil C1-6, aril C6-10, aril C6-10-alquiI C1-6, heterociclil C3-6, heterociclil C3-6-alquiI C1-6 y heterociclil C2-9 son opcionalmente sustituidos por uno o más grupos seleccionados de alquilC1-6, alquil C1-6 halogenado, carboxi, halogeno, ciano, nitro, oxo, alcoxi C1-4, haloalcoxi C1-4, hidroxi, cicloalquil C3-6-alcoxi C1-4, heterocicloalquil C3-6, -(CH2)m-C(=O)NR7R8, -C(=O)-(CH2)m-NR7R8, -(CH2)m-S(=O)2NR7R8, -(CH2)mNH-C(=O)NR7R8, -(CH2)m-N(R7)C(=O)R8, -(CH2)m-N(R7)C(=O)-OR8, -(CH2)m-C(=O)-OR7, -(CH2)m-C(=O)R7, -(CH2)m-S(=O)2R7, -(CH2)m-O-C(=O)-R7, -(CH2)m-OR7, y -(CH2)m-NR7R8; R5 es seleccionado de hidrogeno y alquil C1-6, cicloalquil C3-7, heterociclil C1-6, heteroaril yaril C6-10, son opcionalmente sustituidos con uno o más grupos seleccionados de OH, alcoxi C1-4, alcoxi C1-4 halogenado, y halogeno; R7 y R8 son independientemente seleccionados a partir de -H, alquil C1-6, aril C6-10, heterociclil C1-5, ycicloalquil C3-6-alquil C0-4, donde dichos alquil C1-6, aril C6-10, heterociclil C1-5, y cicloalquil C3-6-alquil C0-4 son opcionalmente sustituidos con uno o más grupos seleccionados de -OH, metoxi, etoxi y halogeno; y m es 0, 1, 2 o 3, con lacondicion de que al menos uno de R1, R2, R3 y R4 no sea hidrogeno con la condicion adicional de que el compuesto no sea seleccionado de 5-[2-(4-{4-[(4-clorofenil)amino]-6-isopropil-7-oxo-6,7-dihidro-5H-pirrolo[3,4-d]-pirimidin-2-il}piperazin-1-il)-2-oxoetil]imidazolidina-2,4-diona; 2-amino-4-anilino-5,6-dihidro-7H-pirrolo[3,4-d]pirimidin-7-ona; 1-[4-[4-clorofenil)amino]-6,7-dihidro-6-(1-metiletil)-7-oxo-5H-pirrolo[3,4-d]pirimidin-2-il]-4-[2-(hidroxiimino)-1-oxopropil]-piperazina; 4-[(4-clorofenil)amino]-5,6-dihidro-2-(4-morfolinil)-6-[2-(4-morfolinil)etil)-7H-pirrolo[3,4-d]pirimidin-7-ona; 4-[(2-aminofenil)amino]-5,6-dihidro-5-imino-6-propil-2-(1-pirrolidinil)-7H-pirrolo[3,4-d]pirimidin-7-ona; 5,6-dihidro-5-imino-6-propil-4-(propilamino)-2-(1-pirrolidinil)-7H-pirrolo[3,4-d]pirimidin-7-ona; 5-amino-2-(1-piperidinil)-4-(propilamino)-7H-pirrolo[3,4-d]pirimidin-7-ona; 4,5-diamino-2-(1-piperidinil)-7H-Pirrolo[3,4-d]pirimidin-7-ona; 5-amino-4-(1-piperidinil)-2-(1-pirrolidinil)-7H-pirrolo[3,4-d]pirimidin-7-ona; 5-amino-4-(propilamino)-2-(1-pirrolidinil)-7H-pirrolo[3,4-d]pirimidin-7-ona; 4,5-diamino-2-(1-pirrolidinil)-7H-pirrolo[3,4-d]pirimidin-7-ona; N-[6,7-dihidro-7-oxo-6-fenil-4-(1-piperidinil)-5H-pirrolo[3,4-d]pirimidin-2-il]-N-fenil- benzamida; 5-[(dimetilamino)metileno]-5,6-dihidro-6-fenil-2-(fenilamino)-4-(1-piperidinil)-7H-pirrolo[3,4-d]pirimidin-7-ona; 2,4-bis(dimetilamino)-5,6-dihidro-6-fenil-7H-pirrolo[3,4-d)pirimidin-7-ona; 5,6-dihidro-6-fenil-2-(fenilamino)-4-(1-piperidinil)-7H-pirrolo[3,4-d]pirimidin-7-ona; 5,6-dihidro-6-metil-2,4-di-1-piperidinil-7H-pirrolo[3,4-d}pirimidin-7-ona; 4-anilino-6-butil-2-(butilamino)-5,6-dihidro-7H-pirrolo[3,4-d]pirimidin-7-ona; 4-anilino-2-p-anisidino-5,6-dihidro-6-(p-metoxifenil)-7H-pirrolo[3,4-d]pirimidin-7-ona; 2-anilino-5,6-dihidro-4-(p-hidroxianilino)-6-fenil-7H-pirrolo[3,4-d]pirimidin-7-ona; 2,4-dianilino-5,6-dihidro-6-fenil-7H-pirrolo[3,4-d]pirimidin-7-ona; 4-[(2-cloroetil)amino]-5,6-dihidro-6-fenil-2-piperidino-7H-pirrolo[3,4-d]pirimidin-7-ona; 4-anilino-5,6-dihidro-6-(p-metoxifenil)-2-morfolino-7H-pirrolo[3,4-d]pirimidin-7-ona; 4-anilino-5,6-dihidro-6-(p-metoxifenil)-2-piperidino-7H-pirrolo[3,4-d]pirimidin-7-ona; 2-hidroxietil éster del ácido 5,7-dihidro-2,4-dimorfolino-7-oxo-6H-pirrolo[3,4-d]pirimidina-6-acético; 6-bencil-5,6-dihidro-2,4-dimorfolino-7H-pirrolo[3,4-d]pirimidin-7-ona; 5,6-dihidro-2,4-dimorfolino-6-fenil-7H-pirrolo[3,4-d]pirimidin-7-ona; 5,6-dihidro-6-(2-hidroxietil)-2,4-dipiperidino-7H-pirrolo[3,4-d]pirimidin-7-ona; y 5,6-dihidro-6-fenil-2,4-di-1-piperidinil-7H-pirrolo[3,4-d]pirimidin-7-ona.
ARP080101934A 2007-05-08 2008-05-07 Compuestos nitrogenados condensados, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos particularmente, en el tratamiento del dolor y/o la vejiga hiperactiva. AR066475A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91658807P 2007-05-08 2007-05-08

Publications (1)

Publication Number Publication Date
AR066475A1 true AR066475A1 (es) 2009-08-19

Family

ID=39943763

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101934A AR066475A1 (es) 2007-05-08 2008-05-07 Compuestos nitrogenados condensados, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos particularmente, en el tratamiento del dolor y/o la vejiga hiperactiva.

Country Status (16)

Country Link
US (1) US20090099195A1 (es)
EP (1) EP2155751A1 (es)
JP (1) JP2010526138A (es)
KR (1) KR20100017688A (es)
CN (1) CN101687875A (es)
AR (1) AR066475A1 (es)
AU (1) AU2008246351A1 (es)
BR (1) BRPI0811436A2 (es)
CA (1) CA2686707A1 (es)
CL (1) CL2008001335A1 (es)
MX (1) MX2009011997A (es)
PE (1) PE20090816A1 (es)
RU (1) RU2009140469A (es)
TW (1) TW200846001A (es)
UY (1) UY31068A1 (es)
WO (1) WO2008136756A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367826A4 (en) * 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
EP2399910B1 (en) 2009-02-13 2014-04-02 Shionogi&Co., Ltd. Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
ES2442797T3 (es) 2009-11-18 2014-02-13 Neomed Institute Compuestos de benzoimidazol y sus utilizaciones
PH12012502079A1 (en) 2010-04-16 2013-02-11 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
WO2011133659A2 (en) * 2010-04-20 2011-10-27 Emory University Inhibitors of hif and angiogenesis
JP5594706B2 (ja) 2010-08-10 2014-09-24 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
EP2604260B1 (en) * 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
US9381260B2 (en) 2011-12-27 2016-07-05 Emory University Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents
JP6124351B2 (ja) 2012-02-09 2017-05-10 塩野義製薬株式会社 複素環および炭素環誘導体
DK3381917T3 (da) 2013-01-31 2021-10-18 Bellus Health Cough Inc Imidazopyridinforbindelser og anvendelser deraf
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
WO2016088838A1 (ja) * 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
CN110256418B (zh) 2014-12-09 2023-01-20 拜耳公司 1，3-噻唑-2-基取代的苯甲酰胺
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017209267A1 (ja) * 2016-06-03 2017-12-07 塩野義製薬株式会社 プリン誘導体
JP6856471B2 (ja) * 2017-01-04 2021-04-07 株式会社トクヤマ ラクトン化合物の製造方法、および該ラクトン化合物を使用したビオチンの製造方法
US11365194B2 (en) 2017-09-27 2022-06-21 Kagoshima University Analgesic drug using PAC1 receptor antagonistic drug
ES2914377T3 (es) 2017-10-27 2022-06-10 Bayer Ag Derivados novedosos de pirazolo-pirrolo-pirimidin-diona como inhibidor de P2X3
CN107778282B (zh) * 2017-11-03 2020-04-10 中山大学 喹啉-吲哚衍生物及其在制备治疗阿尔茨海默病的药品中的应用
WO2019180627A1 (en) * 2018-03-21 2019-09-26 Piramal Enterprises Limited AN IMPROVED ASYMMETRIC SYNTHESIS OF alpha-(DIARYLMETHYL) ALKYL AMINES
JP7578602B2 (ja) 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド Ｐ２ｘ３修飾薬での治療
JP7501920B2 (ja) 2019-02-27 2024-06-18 国立大学法人 鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痒薬
CN114929706A (zh) * 2019-09-29 2022-08-19 百济神州有限公司 Kras g12c的抑制剂
CN114555597B (zh) * 2019-10-12 2024-06-04 浙江迈同生物医药有限公司 异柠檬酸脱氢酶（idh）抑制剂
KR20220113385A (ko) * 2019-12-10 2022-08-12 상하이 한서 바이오메디컬 컴퍼니 리미티드 피라졸-함유 다환식 유도체 억제제, 그의 제조 방법 및 그의 적용
CN113135924B (zh) * 2020-01-19 2024-04-26 广东东阳光药业股份有限公司 嘧啶衍生物及其在药物中的应用
US20210292330A1 (en) * 2020-02-28 2021-09-23 Erasca, Inc. Pyrrolidine-fused heterocycles
PE20230106A1 (es) * 2020-03-13 2023-01-25 Astrazeneca Ab Compuestos de pirimidina fusionados como moduladores de kcc2
TW202208355A (zh) * 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
EP4147701A4 (en) 2020-05-08 2024-06-12 Kagoshima University Antidepressant/anxiolytic drug in which pac1 receptor antagonist is used
CA3195519A1 (en) 2020-09-18 2022-03-24 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022067462A1 (en) * 2020-09-29 2022-04-07 Beigene (Beijing) Co., Ltd. Process for preparing inhibitors of kras g12c
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
US20240109868A1 (en) * 2022-08-29 2024-04-04 Miracure Biotechnology Limited Ep300/cbp modulator, preparation method therefor and use thereof
WO2025188953A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051440A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Combination drugs
DE60237425D1 (de) * 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases

Also Published As

Publication number Publication date
PE20090816A1 (es) 2009-07-25
JP2010526138A (ja) 2010-07-29
CL2008001335A1 (es) 2008-11-14
US20090099195A1 (en) 2009-04-16
CA2686707A1 (en) 2008-11-13
MX2009011997A (es) 2009-11-19
TW200846001A (en) 2008-12-01
RU2009140469A (ru) 2011-06-20
CN101687875A (zh) 2010-03-31
KR20100017688A (ko) 2010-02-16
BRPI0811436A2 (pt) 2014-12-16
EP2155751A1 (en) 2010-02-24
UY31068A1 (es) 2009-01-05
AU2008246351A1 (en) 2008-11-13
WO2008136756A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
AR066475A1 (es) Compuestos nitrogenados condensados, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos particularmente, en el tratamiento del dolor y/o la vejiga hiperactiva.
TWI297690B (en) Pyrrolo pyrimidines,pharmaceutical composition for treating a patient suffering from or susceptible to a disease or medical condition in which cathepsin k is implicated comprising the same,and process for the preparation thereof
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
TWI466885B (zh) 含氮螺環化合物及其醫藥用途
RU2011116447A (ru) Модуляторы амилоида бета
CL2011000880A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer.
NZ598907A (en) Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
JP2013509438A5 (es)
JP2011511003A5 (es)
JP2010509399A5 (es)
JP2010511709A5 (es)
AR008577A1 (es) Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
EP2864295A2 (en) NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF
IL156609A (en) Pyrazolo [1, a5] Pyrimidines compressed by cyclocalyptic or heterocyclic rings and repellents containing them
JP2013500975A5 (es)
IL151234A (en) History of pyrolopyrimidinone, preparation and use process
JP2007521287A5 (es)
JP2017531672A5 (es)
AU2006285599A1 (en) Pyridazinone derivatives used for the treatment of pain
JP2010539169A (ja) ヒスタミンｈ４受容体のチエノ−及びフロ−ピリミジン調節物質
RU2010148534A (ru) Производные имидазолидинона в качестве ингибиторов в 11b-hsd1
CN104640865B (zh) 作为激酶抑制剂的二氢吡咯烷子基-嘧啶
JP2023554062A (ja) 新規アリール－ピリド－ピリミジン－オン誘導体

Legal Events

Date Code Title Description
FB Suspension of granting procedure